87 - Catalent Biologics opens Phoenix, a €34 million project

The American group Catalent Biologics, one of the world leaders in advanced technologies for the development and manufacture of injectable drugs, has just inaugurated its European biomedicine center in Limoges. This "34 million euro project named 'Phoenix', also a France Relance winner, has transformed the Limoges site into a world-class facility to support the development of early-phase, small-scale commercial biological drugs" commented Mike Riley, president of Catalent, Biotherapeutics.

80 recruitments are also planned by 2025.   The site therefore changes dimension with the installation of a new production line which will make France a little less dependent vis-à-vis the states which produce biomedicines. This new filling line for sterile injectable solutions will enable it to seek out new customers while the new laboratory will participate in the development of new molecules. “Limoges will now work closely with other Catalent facilities in Europe and the United States to provide globally integrated solutions for a range of therapies. »

https://biologics.catalent.com/catalent-news/catalent-biologics-completes-30-million-project-for-biopharmaceutical-development-and-drug-product-manufacturing-in-limoges-france/